Sign In
Buy LGND
$234.40
+1.64 (+0.705%)
At Close: Jun 03, 2026
This announcement contains inside information for the purposes of the retained UK version of the EU Market Abuse Regulation (EU) 596/2014 ("UK MAR"). Arecor Therapeutics plc (“Arecor” or the
Ligand to Participate in September Investor Conferences
04:00pm, Tuesday, 19'th Aug 2025
JUPITER, Fla., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza wi
Ligand Announces Closing of Convertible Senior Notes Offering
04:00pm, Thursday, 14'th Aug 2025
JUPITER, Fla., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) (“Ligand”) announced today that it completed its previously announced offering (the “offerin
Ligand Announces Pricing of $400 Million Convertible Senior Notes Offering
11:46pm, Monday, 11'th Aug 2025
JUPITER, Fla., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) (“Ligand”) announced today the pricing of $400.0 million aggregate principal amount of 0.75% co
Ligand Announces Proposed Offering of $400 Million of Convertible Senior Notes Due 2030
07:00am, Monday, 11'th Aug 2025
JUPITER, Fla., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) (“Ligand”) announced today its intention to offer $400.0 million aggregate principal amount of
Ligand Pharmaceuticals Incorporated (LGND) Q2 2025 Earnings Call Transcript
08:01pm, Thursday, 07'th Aug 2025
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND ) Q2 2025 Earnings Conference Call August 7, 2025 8:30 AM ET Company Participants Lauren Hay - Corporate Participant Melanie Herman - Corporate Partici
Ligand (LGND) Q2 Revenue Jumps 15%
09:10am, Thursday, 07'th Aug 2025
Ligand Pharmaceuticals (LGND -0.34%), a biopharma company known for earning royalties from a broad portfolio of drugs, announced results for the second quarter of 2025 on August 7, 2025. The company e
Ligand Reports Second Quarter 2025 Financial Results and Raises Guidance
07:00am, Thursday, 07'th Aug 2025
Second quarter performance driven by strong portfolio royalty revenue growth of 57% 2025 full year revenue guidance increased to $200 million - $225 million (previously $180 million - $200 million) an
Ligand to Report Second Quarter 2025 Financial Results on August 7, 2025
07:00am, Thursday, 24'th Jul 2025
JUPITER, Fla., July 24, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report second quarter 2025 financial results on Thursday, August 7, 202
Ligand Partner Pelthos Therapeutics Launches ZELSUVMI™
08:00am, Thursday, 10'th Jul 2025
JUPITER, Fla., July 10, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its partner Pelthos Therapeutics Inc. (NYSE American: PTHS) has commercially la
Ligand Announces Completion of Pelthos Therapeutics Merger with Channel Therapeutics
07:00am, Wednesday, 02'nd Jul 2025
Pelthos plans to launch ZELSUVMI™ for the treatment of Molluscum contagiosum infections in July 2025 Concurrent with the closing of the merger, Ligand has invested $18 million in the combined compan
Pelthos Therapeutics Completes Merger with Channel Therapeutics and Closes $50.1 Million Private Placement
07:00am, Wednesday, 02'nd Jul 2025
The combined company plans to launch ZELSUVMI™ for the treatment of molluscum contagiosum infections in July 2025 Concurrent with the closing of the merger, the combined company closed on a $50.1 mi
Ligand Pharmaceuticals: Attractive Royalty Model Powers Forward
02:47pm, Tuesday, 24'th Jun 2025
I maintain my Buy rating on Ligand Pharmaceuticals due to its strong growth trajectory and diversified portfolio. Ligand offers investors exposure to dozens of therapies, reducing risk and increasing
Ligand Announces 2025 Investor Day in New York City
07:00am, Wednesday, 11'th Jun 2025
JUPITER, Fla., June 11, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will host an Investor Day in New York City on Tuesday, December 9, 2025 at 1
Ligand to Ring the Nasdaq Opening Bell on May 19, 2025
07:00am, Wednesday, 14'th May 2025
JUPITER, Fla., May 14, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that the company will ring The Nasdaq Stock Market Opening Bell on Monday, May 19, 20
